Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.

Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...